EMISPHERE TECHNOLOGIES, INC. (LON:EMIS) Files An 8-K Other Events
Item 8.01. Other Events.

On August 20, 2014, Emisphere Technologies, Inc. (the “Company”) entered into a series of agreements with MHR Capital Partners Master Account LP, MHR Capital Partners (100) LP, MHR Institutional Partners II LP, and MHR Institutional Partners IIA LP (collectively, “MHR”), including (a) the Second Amended and Restated Convertible Reimbursement Promissory Notes (the “Reimbursement Notes”), (b) a Senior Secured Loan Agreement (the “Loan Agreement”), and (c) a Royalty Agreement (the “Royalty Agreement”).

The terms of the Reimbursement Notes and Loan Agreement require the Company to prepay amounts outstanding thereunder using 50% of certain proceeds (the “Proceeds”) paid to the Company, including $14 million received by the Company on October 26, 2015 in connection with certain licensing agreements with Novo Nordisk AS. Further, the terms of the Royalty Agreement require the Company to pay to MHR annual royalties on net sales of the Company’s oral Eligen^® B12 product (“Royalties”).

On December 1, 2016, MHR agreed to further extend the payment of the Proceeds and Royalties to December 16, 2016.

Copies of the Reimbursement Notes, Loan Agreement and Royalty Agreement were filed by the Company in its Quarterly Report on Form 10-Q for the quarter ending September 30, 2014, and a summary of their material terms was filed in the Company’s Current Report on Form 8-K filed with the SEC on August 21, 2014.

About EMISPHERE TECHNOLOGIES, INC. (LON:EMIS)

EMIS Group plc is a provider of healthcare software, information technology and related services in the United Kingdom. The principal activity of the Company is the design of computer software for healthcare professionals, mainly general practitioners, community pharmacists, secondary and specialist care providers and other clinicians, together with the hosting, provision of specialist information communication technology (ICT) infrastructure and support of computer systems for healthcare professionals and other related users. It operates through three segments: Primary & Community Care; Community Pharmacy, and Secondary & Specialist Care. The Company provides screening services to patients under the EMIS Care brand. It provides diabetic eye screening software and other ophthalmology-related solutions. Its systems are used to manage hospital pharmacy and prescribing, unscheduled care and electronic patient records, and electronic messaging and order communications.

EMISPHERE TECHNOLOGIES, INC. (LON:EMIS) Recent Trading Information

EMISPHERE TECHNOLOGIES, INC. (LON:EMIS) closed its last trading session up +2.99 at 909.49 with 74,412 shares trading hands.